+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying the pharmacokinetics PK and safety of ublituximab given as a subcutaneous SC injection in people with relapsing multiple sclerosis MS. The study evaluates how the drug behaves in the body when injected at different sites and compares the bioavailability when administered by a prefilled pen versus a syringe. This Phase 2 trial is focused on treatment and aims to understand the best method of delivering ublituximab subcutaneously. Participants will receive ublituximab SC either at one of three different injection sites using a syringe or via a prefilled pen. The study randomly assigns participants to receive the drug using either the prefilled pen or the syringe. The treatment period includes assessments up to 12 weeks for primary PK measures and up to 120 weeks for safety and plasma concentration monitoring. During the study, participants will have blood samples taken to measure drug levels and safety will be monitored by tracking any adverse events. They will also report their satisfaction with the injection method through questionnaires up to week 96. The main outcome measured is the area under the curve AUC of ublituximab at steady state by week 12, with longer follow-up to assess plasma concentrations and side effects. The total study duration extends up to nearly three years, ensuring extended safety and treatment evaluation.

Age: 18Years - 65YearsAll GendersPhase 2
44 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.

Age: 18Years - 75YearsAll GendersPhase 3
201 locations
P

Actively Recruiting

Researchers are evaluating the effects of two different doses of CHF10067 zampilimab in adults aged 40 years and older who have idiopathic pulmonary fibrosis IPF. This phase IIb study is randomized, double-blind, and placebo-controlled, conducted at multiple centers worldwide. The aim is to assess how well these doses work, how safe they are, and how well participants tolerate them after 24 weeks of treatment. Participants will be randomly assigned to receive one of two doses of CHF10067 or a placebo. The study treatments are given through intravenous infusion. The trial includes three groups running in parallel. The main treatment period lasts for 24 weeks, during which participants receive the assigned infusions and are monitored closely. During the study, participants will undergo various assessments including lung function tests measuring forced vital capacity FVC at multiple time points up to 30 weeks. Researchers will also measure the concentration of CHF10067 in the blood and evaluate participants quality of life related to pulmonary fibrosis symptoms. Safety and tolerability are monitored throughout the study. The total participation duration covers treatment and follow-up visits until at least Week 30.

Age: 40Years +All GendersPhase 2
19 locations
I

Actively Recruiting

Researchers are studying the use of sodium-glucose cotransporter 2 inhibitors SGLT2i in adults with congenital heart disease ACHD, focusing on how these drugs are prescribed and their safety, tolerability, and possible benefits for heart failure-related outcomes. Heart failure is a leading cause of illness and death in this group, but treatment options are limited. SGLT2i are a new class of medications shown to help in conventional left ventricular heart failure and may work through multiple pathways to improve heart function. This international registry collects real-world data from adult ACHD patients who have been treated with any type and dose of SGLT2i. Data will be gathered from one year before starting the medication up to the most recent follow-up. There are no interventions or changes to care for participants since data collection uses routine clinical records. The registry aims to understand prescription patterns, side effects, discontinuation rates, and heart failure-related clinical and laboratory outcomes. Participants will contribute data from their medical records, including clinical parameters like weight, blood pressure, heart rate, oxygen saturation, laboratory values, echocardiography measurements, and exercise test results. Researchers will monitor safety and tolerability outcomes such as side effects, complications, and mortality over an average follow-up of one year. This study seeks to evaluate the impact of SGLT2i therapy on heart failure progression in ACHD patients through comprehensive real-world observation.

Age: 18Years +All Genders
11 locations
S

Actively Recruiting

Researchers are investigating ischemic stroke cases in patients who are on oral anticoagulants due to atrial fibrillation or other cardioembolic arrhythmias. This observational study, called ASPERA, aims to understand the characteristics of these stroke cases and to evaluate the short- and long-term outcomes of different strategies used to prevent recurrent strokes. The study includes both retrospective and prospective data collection from multiple centers worldwide, coordinated by the University of LAquila. The study has two parts ASPERA-R and ASPERA-P. ASPERA-R collects retrospective data over five years, focusing on baseline demographic, clinical, and neuroimaging features of ischemic strokes in patients on oral anticoagulants. ASPERA-P enrolls patients prospectively for two years with follow-up for five years to assess risks of stroke recurrence and safety events under different secondary prevention approaches, such as continuing or changing oral anticoagulation. Participants will have their data collected at several time points, including hospital admission, discharge, and follow-ups at 90 days, 1 year, and 5 years after stroke. Assessments include clinical evaluations, neuroimaging exams, and monitoring for stroke recurrence, bleeding events, heart attacks, and mortality. The study tracks outcomes to better understand risks and to identify features linked to stroke recurrence and safety events, with total participation lasting up to seven years for prospective patients.

Age: 18Years +All Genders
47 locations
R

Actively Recruiting

Researchers are evaluating the outcomes of different coronary artery bypass grafting techniques in women with heart disease. The trial compares multiple arterial grafting MAG to single arterial grafting SAG to see if using multiple arterial grafts improves major heart and brain-related events and quality of life. This international randomized clinical trial includes 2,300 women to assess differences in survival, stroke, heart attacks, repeat surgeries, and hospital readmissions, as well as physical and mental health. Participants will be randomly assigned to one of two groups. One group receives a single arterial graft using the left internal thoracic artery plus additional venous grafts. The other group receives multiple arterial grafts, including the left internal thoracic artery and at least one other arterial graft such as the right internal thoracic artery or radial artery, with possible additional arterial grafts. The study uses the infrastructure of an existing trial and follows patients for at least 2.5 years after surgery. During the study, researchers collect data on major adverse cardiac and cerebrovascular events, along with quality of life measured by general and disease-specific questionnaires. Physical and mental health symptoms are also assessed. Follow-up includes tracking deaths, strokes, heart attacks, repeat procedures, and hospital stays. The trial aims to provide detailed information on outcomes and quality of life in women undergoing coronary bypass surgery over a long-term period.

Age: 18Years +FEMALEPhase Not Applicable
146 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
R

Actively Recruiting

Researchers are studying cancer-related cardiovascular toxicity, which includes heart problems caused by chemotherapy drugs and radiotherapy in people with cancer. The goal is to identify ways to predict, prevent, and treat heart damage related to cancer treatments. This observational study aims to better understand these cardiovascular risks in cancer patients to improve care. Participants include those newly diagnosed with breast cancer receiving anthracycline-based chemotherapy with or without radiotherapy, trastuzumab, or other anticancer drugs. A subgroup will have their risk assessed using the HFA-ICOS risk score. The study involves following patients at baseline, 3 months, and 1 year to monitor heart health and treatment effects. During the study, participants will attend follow-up visits for assessments, including heart function and survival outcomes. Researchers will track all-cause mortality, cardiovascular mortality, and cancer therapy-related cardiovascular toxicity over about three years. The study collects data to help better understand and manage heart risks linked to cancer treatments.

Age: 18Years +All Genders
5 locations
S

Actively Recruiting

This research aims to evaluate the overall perioperative haemostatic effectiveness of Nuwiq, a recombinant factor VIII, combined with emicizumab prophylaxis in male patients aged 12 and older with severe haemophilia A undergoing major surgery. The study is a prospective, open-label, multinational, multicentre, single-arm trial focused on patients receiving emicizumab who require additional FVIII during surgery. Participants will receive Nuwiq intravenously following the approved prescribing information. Treatment will be administered every 8 to 24 hours as needed until adequate wound healing is achieved. If necessary, treatment may continue for at least another 7 days to maintain factor VIII plasma levels between 30 and 60 IUdL. This regimen aims to provide effective haemostatic cover throughout the surgical and healing period. Throughout the study, participants will be monitored during surgery and until wound healing is complete, typically within 30 days after surgery. Assessments include measuring haemostatic efficacy during and after surgery, blood product transfusion levels, factor VIII plasma levels, thrombin generation, and monitoring for thrombotic events, inhibitor formation, and adverse events. The study duration covers the surgical procedure and a follow-up period to ensure safety and treatment response.

Age: 12Years +MALEPhase 4
18 locations
C

Actively Recruiting

Researchers are evaluating whether giving one dose or two doses of tranexamic acid can safely reduce blood loss in adults aged 65 years or older undergoing surgery for certain hip fractures, specifically pertrochanteric or subtrochanteric femoral fractures. The study aims to determine if two doses lower the need for blood transfusions compared to one dose, whether tranexamic acid helps maintain higher hemoglobin levels after surgery, and if it is safe for this patient group. Participants are randomly assigned to receive either a single intravenous dose of 15 mgkg tranexamic acid before surgery followed by a placebo, or two doses of 15 mgkg tranexamic acid, one before surgery and a second three hours later. All participants undergo standard surgical treatment within 48 hours of hospital admission, with surgery performed under spinal or general anesthesia using fixation devices appropriate for fracture type. Postoperative care includes antibiotic and thromboprophylaxis protocols, and monitoring for complications and adverse events. During the hospital stay, researchers measure blood loss using visible and calculated methods, monitor hemoglobin and other laboratory values daily for up to three days, and record transfusions and complications. Participants are followed for safety and recovery with outpatient visits at 14 days, 1 month, 2 months, and 3 months post-surgery. The main outcome measured is the incidence of blood transfusions through postoperative day 5, with additional outcomes including hemoglobin drop, blood loss, thrombotic events, mortality, and length of hospital stay.

Age: 65Years +All GendersPhase Not Applicable
1 location

1-10 of 15

1